Continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) of rapid-acting insulin analogues and detemir in type 1 diabetic (T1D) pregnant women

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 28, Issue 3, 2015, Pages 276-280

  Mello, Giorgio ^a   Biagioni, Sara ^a   Ottanelli, Serena ^a   Nardini, Camilla ^a   Tredici, Zelinda ^a   Serena, Caterina ^a   Marchi, Laura ^a   Mecacci, Federico ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Continuous subcutaneous insulin infusion; Detemir; Type 1 diabetes in pregnancy

Indexed keywords

GLUCOSE; INSULIN; INSULIN DETEMIR; ANTIDIABETIC AGENT;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; ECHOGRAPHY; FAT MASS; FEMALE; FETUS; GLYCEMIC CONTROL; HUMAN; INFUSION PUMP; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MATERNAL OUTCOME; NEONATAL OUTCOME; NEWBORN; OUTCOME ASSESSMENT; PARAMETERS CONCERNING THE FETUS, NEWBORN AND PREGNANCY; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SELF MONITORING; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; INSULIN INFUSION; PREGNANCY; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, SUBCUTANEOUS; INJECTIONS, SUBCUTANEOUS; INSULIN DETEMIR; INSULIN INFUSION SYSTEMS; PREGNANCY; RETROSPECTIVE STUDIES;

EID: 84923319469     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2014.914922     Document Type: Article

References (29)

1. Jovanovic L, Knops RH, Kim H, et al. Elevated pregnancy losses at high and low extremes of maternal glucose in early normal and diabetic pregnancy: evidence for a protective adaptation in diabetes. Diab Care 2005;28:1113-17
2. Schaefer UM, Songster G, Xiang A, et al. Congenital malformation in offspring of women with hyperglycemia first detected during pregnancy. Am J Obstet Gynecol 1997;177:1165-17
3. Ehrlich SF, Crites YM, Hedderson MM, et al. The risk of large for gestational age across increasing categories of pregnancy glycemia. Am J Obstet Gynecol 2011;204:240.e1-6
4. Plagemann A. Maternal diabetes and perinatal programming. Early Human Develop 2011;87:743-7
5. Jovanovic-Peterson L, Peterson CM, Reed GF, et al. Maternal postprandial blood glucose levels and infant birth weight: the diabetes in early pregnancy study. The National Institute of Child Health and Human Development-diabetes in early pregnancy study. Am J Obstet Gynecol 1991;164:103-11
6. Kinsley B. Achieving better outcomes in pregnancies complicated by type 1 and type 2 diabetes mellitus. Clin Ther 2007;29:S153-60
7. Farrar D, Tuffnell DJ, West J. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev 2007, Issue 3. Review content assessed as up-to-date: 6 September 2011
8. Castorino K, Paband R, Zisser H, Jovanovic L. Insulin pumps in pregnancy: using technology to achieve normoglycemia in women with diabetes. Curr Diab Rep 2012;12:53-9
9. Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-Acting, acylated analog of human insulin. Pharm Rec 2004;21:1498-504
10. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53: 1614-20
11. Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47: 622-9
12. Russell-Jones D, Simpson R, Hylleberg B, et al. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type 1 diabetes mellitus using a basal-bolus regimen. Clin Ther 2004;26:724-36
13. Bartley PC, Bogoev M, Larsen J, Philotheou A. Long term efficacy and safety of insulin detemir compared to neutral protamine Hagedorn insulin in patient with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin as part at meal: a 2-year, randomized, controlled trial. Diabet Med 2008;25: 442-9
14. Durnwald CP, Landon MB. Insulin analogues in the management of the pregnancy complicated by diabetes mellitus. Curr Diab Rep 2011;11:28-34
15. Mathiesen ER, Damm P, Jovanovic L, et al. Basal insulin analogues in diabetic pregnancy: a literature review and baseline results of a randomised controlled trial in type 1 diabetes. Diab Metab Res Rev 2011;27:543-51
16. Torlone E, Di Cianni G, Mannino D, Lapolla A. Insulin analogs and pregnancy: an update. Acta Diabetol 2009;46:163-72
17. Lapolla A, Di Cianni G, Bruttomesso D, et al. Use of insulin detemir in pregnancy: a report on 10 Type 1 diabetic women. Diabet Med 2009;26:1181-2
18. Mathiesen ER, Hod M, Ivanisevic M, et al. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabet Care 2012;35:2012-17
19. Levemir- (insulin detemir [rDNA origin] injection) solution for subcutaneous injection. Initial U.S. Approval: 2005. Revised: 4/2012. Available from: http://www.accessdata.fda.gov/drugsatfda- docs/label/2012/021536S039lbl.pdf
20. Di Cianni G, Fatati G, Lapolla A, et al., from Italian Society of Diabetology (SID) Association of Diabetologists (AMD) Italian Association of Dietetics and Clinical Nutrition (AIDNC). Italian Guidelines for nutritional therapy in diabetic pregnancies. Recommendations. 05/2006
21. Dietary Reference Values of Nutrients and Energy for the Italian population. Revision 2012. Summary of the XXXV National Congress of the Italian Society of Human Nutrition. Bologna; 2012
22. Rasmussen KM, Yaktine AL. Committee to Reexamine IOM (Institute of Medicine) Pregnancy Weight Guidelines; Food and Nutrition Board; Board on Children, Youth and Families. Institute of Medicine and National Research Council of the National Academies. Weight gain during pregnancy. Reexamining the guidelines. Washington, DC: The National Academic Press; 2009
23. Parretti E, Mecacci F, Papini M, et al. Third trimester maternal glucose levels from diurnal profiles in nondiabetic pregnancies. Correlation with sonographic parameters of fetal growth. Diabet Care 2001;24:1319-23
24. Parretti E, Carignani L, Cioni R, et al. Sonographic evaluation of fetal growth and body composition in women with different degrees of normal glucose metabolism. Diabet Care 2003;26:2741-8
25. Bernstein IM, Goram MI, Amini SB, Catalano PM. Differential growth of fetal tissue during the second half of pregnancy. Am J Obstet Gynecol 1997;176:28-32
26. Gardosi J, Chang A, Kalyan B, et al. Customised antenatal growth charts. Lancet 1992;339:283-7
27. Volpe L, Pancani F, Aragona M, et al. Continuous subcutaneous insulin infusion and multiple dose insulin injections in Type 1 diabetic pregnant women: a case-control study. Gynecol Endocrinol 2010;26:193-6
28. Bruttomesso D, Bonomo M, Costa S, et al; the IGCSIIP (Italiano Group for Continuous Subcutaneous Insulin Infusion in Pregnancy). Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or with insuline glargine and multiple daily injections of rapid acting insulin analogues (glargine-MDI). Diabet Metab 2011; 37:426-31
29. Ringholm L, Pedersen-Bjergaard U, Thorsteinsson B, et al. Hypoglycemia during pregnancy in women with type 1 diabetes. Diabet Med 2012;29:558-66